Clinical Trial: A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07684157) titled 'A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis' on June 29.

Brief Summary: This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.

Study Start Date: July 29

Study Type: INTERVENTIONAL

Condition: Rheumatoid Arthritis (RA)

Intervention: DRUG: JAB-8263

Variable dose1, orally Q2D w...